Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2009-12-21 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings Classification · 96% confidence The document is a press release dated December 21, 2009, announcing that the Swedish Medical Products Agency (Läkemedelsverket) has approved a new over-the-counter drug (Xerclear™) for cold sores. It details the drug's efficacy, indication, and planned availability timeline (Q1/Q2 2010). This is an announcement regarding a product approval and market entry, not a comprehensive annual report (10-K), an interim report (IR), or a formal regulatory filing like a proxy statement. Since it is a specific announcement about a product/development, it doesn't fit perfectly into the standard financial filing codes. However, it is a specific corporate announcement that is not covered by the other codes (like DIRS, DIV, MANG, etc.). Given the options, it is most closely related to a general regulatory announcement or a specific corporate update. Since it is a press release announcing a regulatory approval, and there isn't a specific 'Product Approval Announcement' code, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement, or potentially 'Report Publication Announcement' (RPA) if interpreted as announcing the publication of the approval decision, but RNS is a better fit for general regulatory news releases not covered elsewhere. Given the context of financial reporting databases, RNS serves as the catch-all for non-standard regulatory news. The document length (4284 chars) is not extremely short, but it is a press release announcing an event, not the underlying detailed report itself.
2009-12-21 Swedish
Earnings Release 2009
Earnings Release Classification · 95% confidence The document is a press release dated November 19, 2009, detailing positive Phase IIb clinical trial results for the drug valomaciclovir in treating shingles (herpes zoster). It discusses primary endpoints, statistical significance, safety profiles, and future plans for Phase III trials. This content strongly aligns with an Earnings Release (ER) which typically announces key financial or operational results, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format and focus on trial results, it functions as a major operational update. Since it is a detailed announcement of results rather than just a brief summary, and it is not a full annual/interim report, ER is the most appropriate classification for a significant operational/clinical result announcement. It is not a transcript (CT), a formal regulatory filing like 10-K, or a management discussion (MDA) which usually accompanies financial statements. FY 2009
2009-11-19 Swedish
Earnings Release 2009
Earnings Release Classification · 95% confidence The document is explicitly titled as a "Press Release" dated November 19, 2009, announcing positive results from a Phase 2b clinical trial for a drug (EPB-348) in treating shingles. This content—announcing trial results, efficacy data, safety profiles, and quotes from the CEO and lead investigator—is characteristic of an Earnings Release (ER) or a general corporate announcement regarding clinical progress. Since it is a press release detailing financial/operational results (clinical trial outcomes), the most appropriate classification among the provided options is 'ER' (Earnings Release), as these often encompass key operational updates beyond just quarterly financials, especially for biotech/pharma companies. It is not a full Annual Report (10-K), an Audit Report (AR), or a formal Investor Presentation (IP). Given the nature of the announcement (positive trial results), ER is the best fit for a key operational update release. FY 2009
2009-11-19 English
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is titled as a "Press Release" dated November 4, 2009, announcing the presentation of new Phase IIa clinical trial data for a drug (TMC435) at a medical meeting (AASLD). It details study results, safety profiles, and ongoing/planned clinical trials. This content is characteristic of an announcement regarding clinical trial progress or scientific findings, which is typically released to investors and the public via a press release. Since it is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a specific management/governance document, and it is not merely announcing the publication of a report (RPA), it best fits the general category for investor-focused updates that aren't strictly earnings or capital structure changes. Given the options, this type of scientific/clinical update often falls under general Regulatory Filings (RNS) if a more specific category like 'Clinical Trial Update' is unavailable, or sometimes it is grouped with Earnings Releases (ER) if it contains key performance indicators, but here it is purely scientific data presentation. Since RNS is the fallback for miscellaneous regulatory announcements, and this is a public announcement of data, RNS is the most appropriate fit among the provided codes for a non-standard, non-financial-statement press release.
2009-11-04 English
Regulatory Filings 2009
Regulatory Filings Classification · 86% confidence The document is a press release dated November 4, 2009, detailing interim clinical trial results (Phase IIa) for a drug (TMC435) presented at a medical conference (AASLD congress). It discusses scientific findings, safety profiles, and ongoing/planned clinical studies (Phase IIb). This content is highly specific to scientific/clinical updates rather than standard financial reporting (like 10-K, ER, or IR). Since there is no specific category for clinical trial updates or scientific presentations, and it is not a formal regulatory filing like a 10-K or a general earnings release, it falls best under the 'Regulatory Filings' (RNS) category as a general announcement that doesn't fit the other specific financial/governance codes. It is not an Investor Presentation (IP) as it is a press release summarizing data, not a structured presentation deck, nor is it an Earnings Release (ER) which focuses on financial performance.
2009-11-04 Swedish
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report ('delårsrapport') for Medivir covering the period 1 January to 30 September 2009. It contains substantive financial data, including net sales, profit/loss, earnings per share, and cash flow, as well as detailed management commentary on business operations and project pipelines. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. 9M 2009
2009-10-21 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.